Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Naval Daver, MD, Krystal Watkins, Callum M Sloss, PhD, Patrick A Zweidler-McKay, MDPhD, Angela Romanelli, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136791

Published: 2020

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-139903

Published: 2020

Journal Articles

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139081

Published: 2020

Journal Articles

A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval Daver, MD, Kendra L. Sweet, MD MS, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Ahmed Aribi, MD, Daniel J. DeAngelo, MD PhD, Harry P Erba, MDPhD, Giovanni Martinelli, MD, Roland P Walter, MDPhD, Jessica K Altman, MD, Anjali S Advani, MD, Antonio Curti, MDPhD, Callum M Sloss, PhD, Kara E Malcolm, RN, Patrick A Zweidler-McKay, MDPhD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-139884

Published: 2020

Journal Articles

IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Elie Traer, MD PhD, Eunice S. Wang, MD, Harry P. Erba, MD PhD, William Blum, MD, Cecilia Arana-Yi, MD, Callum M. Sloss, Kerry Culm-Merdek, Jeanette Towles, Patrick A. Zweidler-McKay, MDPhD, Daniel J. DeAngelo, MD

Blood (2017) 130 (Supplement 1): 1312.

https://doi.org/10.1182/blood.V130.Suppl_1.1312.1312

Published: 2017

Journal Articles

Intensification of Oral Methotrexate Is Not Superior to Standard Methotrexate Dosing during Maintenance in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

Anne Angiolillo, MD, Reuven Schore, MD, Meenakshi Devidas, Xiaomin Lu, PhD, Karen R. Rabin, MD PhD, Patrick A. Zweidler-McKay, MDPhD, Michael Borowitz, MD PhD, Brent Wood, MDPhD, Andrew J. Carroll, III, PhD, Nyla A. Heerema, PhD, Cindy Wang, MS, Kelly Maloney, MD, Naomi Winick, MD, William L. Carroll, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD

Blood (2017) 130 (Supplement 1): 140.

https://doi.org/10.1182/blood.V130.Suppl_1.140.140

Published: 2017

Journal Articles

Genomic and Outcome Analyses of Philadelphia Chromosome-like (Ph-like) NCI Standard Risk B-Acute Lymphoblastic Leukemia (SR B-ALL) Patients Treated on Children's Oncology Group (COG) AALL0331

Blood (2017) 130 (Supplement 1): 477.

https://doi.org/10.1182/blood.V130.Suppl_1.477.477

Published: 2017

Journal Articles

CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia

Evgeniya Angelova, MD PhD, Charlene Audette, Yelena Kovtun, PhD, Naval Daver, MD, Sa A. Wang, MD, Sherry Pierce, BSN, BA, Sergej Naumovich Konoplev, MD PhD, Jeffrey L. Jorgensen, MD PhD, Marina Konopleva, MD PhD, Patrick A. Zweidler-McKay, MDPhD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Joseph David Khoury, MD

Blood (2017) 130 (Supplement 1): 2718.

https://doi.org/10.1182/blood.V130.Suppl_1.2718.2718

Published: 2017

Journal Articles

Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group

Etan Orgel, MD MS, Thomas B. Alexander, MDMPH, Brent Wood, MDPhD, Samir Kahwash, MD, Meenakshi Devidas, Yunfeng Dai, PhD, Todd A Alonzo, PhD, Charles G. Mullighan, MBBS, MD, Hiroto Inaba, MD, Stephen P. Hunger, MD, Alan S Gamis, MD MPH, Andrew J. Carroll, III, PhD, Nyla A. Heerema, PhD, Jason Berman, MD, William G Woods, MD, Mignon L. Loh, MD, Patrick A. Zweidler-McKay, MDPhD, John T Horan, MD

Blood (2017) 130 (Supplement 1): 883.

https://doi.org/10.1182/blood.V130.Suppl_1.883.883

Published: 2017

Journal Articles

A Novel DLL1-Anti-CD19 Chimeric Protein Effectively Targets Notch Activation to B-Cell Acute Lymphoblastic Leukemia and Induces Cell Death

Rebecca E Wiersma, Sankaranarayanan Kannan, PhD, Srinivas S. Somanchi, PhD, Lizhi Zeng, Patrick A. Zweidler-McKay, MDPhD

Blood (2015) 126 (23): 4833.

https://doi.org/10.1182/blood.V126.23.4833.4833

Published: 2015

Journal Articles

A Novel Notch/NRF2 Mechanism Mediates Reductive Stress in Acute Myeloblastic Leukemia (AML): A Therapeutic Strategy to Overcome Chemoresistance

Sankaranarayanan Kannan, PhD, Patrick A. Zweidler-McKay, MDPhD

Blood (2015) 126 (23): 4834.

https://doi.org/10.1182/blood.V126.23.4834.4834

Published: 2015

Journal Articles

The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial

Patrick A. Zweidler-McKay, MDPhD, Daniel J. DeAngelo, MDPhD, Dan Douer, MD, Hervé Dombret, MD, Oliver G. Ottmann, MD, Norbert Vey, MD, Deborah A. Thomas, MD, Lili Zhu, MSc, Fei Huang, PhD, Gaurav Bajaj, PhD, Bruce S. Fischer, MD

Blood (2014) 124 (21): 968.

https://doi.org/10.1182/blood.V124.21.968.968

Published: 2014

Journal Articles

Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Koji Sasaki, Ildefonso Ismael Rodriguez-Rivera, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Michael J. Burke, MD, Patrick A. Zweidler-McKay, MDPhD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 4538.

https://doi.org/10.1182/blood.V124.21.4538.4538

Published: 2014

NARROW

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Intensification of Oral Methotrexate Is Not Superior to Standard Methotrexate Dosing during Maintenance in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

Genomic and Outcome Analyses of Philadelphia Chromosome-like (Ph-like) NCI Standard Risk B-Acute Lymphoblastic Leukemia (SR B-ALL) Patients Treated on Children's Oncology Group (COG) AALL0331

CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia

Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group

A Novel DLL1-Anti-CD19 Chimeric Protein Effectively Targets Notch Activation to B-Cell Acute Lymphoblastic Leukemia and Induces Cell Death

A Novel Notch/NRF2 Mechanism Mediates Reductive Stress in Acute Myeloblastic Leukemia (AML): A Therapeutic Strategy to Overcome Chemoresistance

The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial

Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only